Hostname: page-component-78c5997874-g7gxr Total loading time: 0 Render date: 2024-11-16T09:38:12.627Z Has data issue: false hasContentIssue false
  • English
  • Français

Changes in the cytokine profile in first episode, drug-naïve patients with psychosis after short-term antipsychotic treatment

Published online by Cambridge University Press:  23 March 2020

P. Petrikis ,
P. Voulgari ,
V. Boumba ,
D. Archimandriti ,
P. Skapinakis  and
V. Mavreas
P. Petrikis
Affiliation:
Department of Psychiatry, Ioannina, Greece
P. Voulgari
Affiliation:
Ioannina School of Medicine, Department of Internal Medicine, Ioannina, Greece
V. Boumba
Affiliation:
Ioannina School of Medicine, Laboratory of Internal Medicine and Toxicology, Ioannina, Greece
D. Archimandriti
Affiliation:
Ioannina School of Medicine, Department of Internal Medicine, Ioannina, Greece
P. Skapinakis
Affiliation:
Ioannina School of Medicine, Department of Psychiatry, Ioannina, Greece
V. Mavreas
Affiliation:
Ioannina School of Medicine, Department of Psychiatry, Ioannina, Greece

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

An increasing body of evidence suggests that antipsychotic medication can cause immunological changes that could be attributed to the amelioration of psychotic symptoms or the metabolic side effects of the drugs. So far, the results of the studies remain controversial.

Objective

Our aim was to compare the levels of interleukin (IL) IL-2, IL-6 and transforming growth factor-β2 (TGF-β2) in drug-naïve, first-episode patients with psychosis before and after six weeks of antipsychotic medication.

Methods

Thirty-nine first episode patients with psychosis were enrolled in the study. Serum levels of IL-2, IL-6 and TGF-β2 were measured by enzyme linked immunosorbent assay (ELISA) before and six weeks after the initiation of antipsychotic medication. In addition, clinical psychopathology was assessed using Positive and Negative Syndrome Scale (PANSS) before and after treatment.

Results

Serum levels of IL-2 were significantly higher in the study group six weeks after the initiation of antipsychotic treatment (P < 0.001) while TGF-β2 levels were decreased (P < 0.001) and IL-6 levels were slightly reduced (P < 0.004).

Conclusion

The changes in cytokine levels may be attributed to the action of antipsychotic medication and the remission of psychopathology. The reduction in TGF-β2 levels is observed in all patients and with all antipsychotic medications used. TGF-β2 may be a marker of clinical efficacy.

Disclosure of interest

The authors have not supplied their declaration of competing interest.

Type
e-Poster Walk: Psychopharmacology and pharmacoeconomics and psychoneuroimmunology
Information
European Psychiatry , Volume 41 , Issue S1: Abstract of the 25th European Congress of Psychiatry , April 2017 , pp. S371
Copyright
Copyright © European Psychiatric Association 2017
Submit a response

Comments

No Comments have been published for this article.